Jane Huang - Jun 16, 2021 Form 4 Insider Report for BeiGene, Ltd. (BGNE)

Role
CMO, Hematology
Signature
/s/ Qing Nian, as Attorney-in-Fact
Stock symbol
BGNE
Transactions as of
Jun 16, 2021
Transactions value $
-$152,733
Form type
4
Date filed
6/21/2021, 04:45 PM
Previous filing
Jun 10, 2021
Next filing
Jun 30, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BGNE Ordinary Shares Award $0 +25.4K +9.09% $0.00 304K Jun 16, 2021 Direct F1
transaction BGNE American Depositary Shares Sale -$153K -469 -100% $325.66 0 Jun 18, 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BGNE Share Option (Right to Buy) Award $0 +157K $0.00 157K Jun 16, 2021 Ordinary Shares 157K $26.53 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.
F2 Each American Depositary Share ("ADS") represents 13 Ordinary Shares.
F3 The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.
F4 The number of securities underlying the option and the exercise price therefor are represented in ordinary shares.
F5 These securities vest over a four-year period as follows: 25% on June 16, 2022, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.